|
05.20.2008
|
Presentation to GMiA conference, Sydney 21 May 2008
|
|
09.16.2007
|
How does timing of 1st non-innovator patent affect the period of monopoly for a new drug?
Mondaq most popular article — September 2007
|
|
08.20.2007
|
Published on ipFrontline
|
|
08.07.2007
|
Update and brief strategy analysis
|
|
08.05.2007
|
IAM-Magazine, August/September 2007, Issue 25
|
|
07.17.2007
|
Are generic's launching earlier than ever?
Mondaq most popular article — July 2007
|
|
12.20.2006
|
(Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC(No 2) [2006] FCA 1787
|
|
12.07.2006
|
(Ranbaxy v Michael O Leavitt, US Court of Appeals for the District of Columbia, 14 Nov. 2006)
Mondaq most popular article — December 2006
|
|
10.14.2006
|
Journal of Intellectual Property Law and Practice, Oxford University Press, 2006, 1(12): 748
|
|
08.16.2006
|
(Pfizer Inc. v Ranbaxy Laboratories CAFC 06-1179 (2006))
|
|
07.26.2006
|
Strategic points from the US Appeals Board - In re N.V. Organon
|
|
07.13.2006
|
|
|
07.10.2006
|
|
|
06.23.2006
|
|
|
06.19.2006
|
|
|
06.02.2006
|
Merck Sharp & Dohme DE Espana S.A. v Bexal Farmaceutica, S.A; Provincial High Court of Madrid (00089/2006)
|
|
05.29.2006
|
|
|
05.22.2006
|
Mayne Pharma v Debiopharm SA & Sanofi-Synthélabo [2006] EWHC 1123 (Pat)
|
|
05.17.2006
|
|
|
04.13.2006
|
(Aventis Pharma SA v Amphastar Pharmaceuticals [2006] CAFC - 10 April 2006)
|
|
04.11.2006
|
Journal of Intellectual Property Law and Practice, Oxford University Press, 2006, Volume 1, Number 8, p 502
|
|
03.30.2006
|
|
